UHBMyeloid

111 posts

UHBMyeloid banner
UHBMyeloid

UHBMyeloid

@UhbTeam

State-of-the-Art diagnostics and management of myeloid malignancies in Birmingham.

Birmingham Katılım Kasım 2022
128 Takip Edilen86 Takipçiler
UHBMyeloid retweetledi
NEJM
NEJM@NEJM·
In a phase 1 study of the oral p53 reactivator rezatapopt in heavily pretreated patients with TP53 Y220C–mutated solid tumors, the most common adverse events were nausea and vomiting, and the overall response was 20%. Full PYNNACLE study results: nej.md/3OIQC5P Science behind the Study: Restoring Function to a Variant of p53 in Solid Tumors nej.md/3N0pQW8
NEJM tweet media
English
8
94
241
135.9K
UHBMyeloid retweetledi
Dr Tony Goldstone
Dr Tony Goldstone@goldstone_tony·
ICYMI - Self assessment deadline is now just over 2 weeks away. If you are struggling with what to write regarding your annual allowance, see my video from the weekend below 👇
Dr Tony Goldstone tweet media
Dr Tony Goldstone@goldstone_tony

NEW VIDEO ALERT! 🎥🚨 Help with 25/26 annual allowance & self assessment? Watch below! 👇 Covers: • SA101/SA100 reporting for AA charge • What is scheme pays • Scheme pays cost • SPE2 application (England/Wales/NI/Scotland) youtu.be/CF1Pa5f3uug

English
0
4
2
1.9K
UHBMyeloid retweetledi
Blood Advances
Blood Advances@BloodAdvances·
DNMT3A, TET2, and ASXL1 mutations differentially shape the subsequent evolutionary trajectories of AML from diagnosis through relapse. ow.ly/rXck50VFJea #myeloidneoplasia
Blood Advances tweet media
English
0
15
58
4.6K
UHBMyeloid retweetledi
Charlie Craddock CBE
Charlie Craddock CBE@charliecraddock·
Hugely important talk from @drpramilak on impact of ethnicity on patient outcome in AML. Emerging evidence of distinct disease biology and decreased transplant access contributing to worse outcomes. Vital area for research and action- supports launch of UK Myecare AML Registry.
Charlie Craddock CBE tweet mediaCharlie Craddock CBE tweet mediaCharlie Craddock CBE tweet media
English
1
8
32
2.5K
UHBMyeloid retweetledi
Sridhar Chaganti
Sridhar Chaganti@SridharChaganti·
Brilliant work by my colleague @lymphomule. Most MYC/BCL6r lymphomas harbour a single-hit, reciprocal translocation t(3;8) between MYC and BCL6 (pseudo double-hit) and have better outcomes than t(3;8) negative double-hit cases. doi.org/10.1182/blood.…
Sridhar Chaganti tweet media
English
5
13
47
4.4K
UHBMyeloid retweetledi
Justin Loke
Justin Loke@jloke1·
Thanks to @TheEBMT @Mohty_EBMT Myriam labopin and the ALWP team for this analysis and @charliecraddock for inspiration in clinic!- kinetics of CR induction matters to post allo sct prognosis.
ACS Journal Cancer@JournalCancer

#OpenAccess | Initial response to chemotherapy as determined by number of courses to attain complete remission (CR), retained prognostic relevance even following stem cell transplant in CR. acsjournals.onlinelibrary.wiley.com/doi/full/10.10… @OncoAlert

English
2
4
21
2.5K
UHBMyeloid retweetledi
Yu-Hung Wang
Yu-Hung Wang@Wang_Yu_Hung·
-Loss of #Dnmt3a increases self-renewal of JAK2V617F HSCs and mitigates their attrition upon chronic #pegIFNα Rx -A combination of pegIFNα and AZA can strongly decrease the JAK2-mut allele burden in MPN driven by JAK2V617F alone doi.org/10.1182/blood.… #MPNsm @BloodJournal
Yu-Hung Wang tweet media
English
1
13
39
3.4K
UHBMyeloid retweetledi
Blood Advances
Blood Advances@BloodAdvances·
Blast-reduction strategies in MPN-AP/BP most commonly result in reversion to chronic phase MPN with significant residual disease burden. ow.ly/sg9A50QMWGa #myeloidneoplasia
Blood Advances tweet media
English
0
9
25
2.2K
UHBMyeloid retweetledi
RC of Pathologists
RC of Pathologists@RCPath·
'We passionately believe that critical appraisal of trials is a core skill that all healthcare professionals should be able to perform.' We interview Drs Rich Buka and Pip Nicholson on their new podcast series discussing non-malignant haematology. ow.ly/Brpo50QQ72u
English
1
5
9
1.3K